Expand ESPR Menu
ESPR MENU

ESPR Latest Press Releases

-- April 7, 2024 --

Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity Globe Newswire 2:45 PM

-- April 1, 2024 --

Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024 Globe Newswire 8:00 AM

-- March 26, 2024 --

Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference Globe Newswire 8:00 AM

-- March 25, 2024 --

Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24 Globe Newswire 4:00 PM

-- March 22, 2024 --

U.S. FDA Approves Broad New Labels for Esperion's NEXLETOL and NEXLIZET to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use Business Wire 6:26 PM
U.S. FDA Approves Broad New Labels for NEXLETOL and NEXLIZET to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use Globe Newswire 3:10 PM
CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events Globe Newswire 11:04 AM

-- February 27, 2024 --

Esperion Reports Fourth Quarter and Full Year 2023 Financial Results Globe Newswire 6:00 AM

-- February 16, 2024 --

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- February 13, 2024 --

Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27 Globe Newswire 8:00 AM

-- February 1, 2024 --

RFK, Esperion Therapeutics Announce 2024 Promotional Schedule Globe Newswire 2:00 PM

-- January 23, 2024 --

Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares Globe Newswire 4:00 PM

-- January 18, 2024 --

Esperion Announces Pricing of $85.1 Million Public Offering of Common Stock Globe Newswire 9:15 PM
Esperion Announces Proposed Public Offering of Common Stock Globe Newswire 4:00 PM

-- January 3, 2024 --

Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation Globe Newswire 7:00 AM

-- December 18, 2023 --

Esperion to Participate in 42nd Annual J.P. Morgan Healthcare Conference Globe Newswire 8:00 AM

-- December 13, 2023 --

U.S. FDA Updates LDL-C Lowering Indication for Esperion's NEXLETOL (bempedoic acid) Tablet and NEXLIZET (bempedoic acid and ezetimibe) Tablet Globe Newswire 4:00 PM